TORONTO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its United States subsidiary, Intellipharmaceutics Ltd., has appointed Ira Baeringer as its Vice President, Business Development, effective February 1, 2012.
